Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
- PMID: 38408567
- DOI: 10.1016/j.jconrel.2024.02.033
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
Abstract
Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to the complex tumor microenvironment that affects the localization and killing ability of the CAR cells. Solid tumors with a strong immunosuppressive microenvironment and complex vascular system are unaffected by CAR cell infiltration and attack. To improve their efficacy toward solid tumors, CAR cells have been modified and upgraded by "decorating" and "pruning". This review focuses on the structure and function of CARs, the immune cells that can be engineered by CARs and the transformation strategies to overcome solid tumors, with a view to broadening ideas for the better application of CAR cell therapy for the treatment of solid tumors.
Keywords: Adoptive cellular immunotherapy; CAR-M; CAR-NK; CAR-T; Chimeric antigen receptor; Solid tumor.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no competing financial interests.
Similar articles
-
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.Mol Cancer. 2023 Jan 30;22(1):20. doi: 10.1186/s12943-023-01723-z. Mol Cancer. 2023. PMID: 36717905 Free PMC article. Review.
-
Recent Advances in CAR-Based Solid Tumor Immunotherapy.Cells. 2023 Jun 11;12(12):1606. doi: 10.3390/cells12121606. Cells. 2023. PMID: 37371075 Free PMC article. Review.
-
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.Stem Cell Res Ther. 2022 Sep 24;13(1):482. doi: 10.1186/s13287-022-03163-w. Stem Cell Res Ther. 2022. PMID: 36153626 Free PMC article. Review.
-
Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.Pharmacol Res. 2022 Oct;184:106454. doi: 10.1016/j.phrs.2022.106454. Epub 2022 Sep 14. Pharmacol Res. 2022. PMID: 36115525 Review.
-
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3. Mol Cancer. 2018. PMID: 29329591 Free PMC article. Review.
Cited by
-
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy.J Hematol Oncol. 2024 Nov 13;17(1):110. doi: 10.1186/s13045-024-01633-7. J Hematol Oncol. 2024. PMID: 39533415 Free PMC article. Review.
-
Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions.Transl Oncol. 2024 Nov;49:102086. doi: 10.1016/j.tranon.2024.102086. Epub 2024 Aug 24. Transl Oncol. 2024. PMID: 39181114 Free PMC article. Review.
-
Natural killer cell-based cancer immunotherapy: from basics to clinical trials.Exp Hematol Oncol. 2024 Oct 16;13(1):101. doi: 10.1186/s40164-024-00561-z. Exp Hematol Oncol. 2024. PMID: 39415291 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
